Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.64 |
| ▸ | PLK1 | P53350 | 1/20 | 0.64 |
| ▸ | AR | P10275 | 1/20 | 0.63 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.60 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.57 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.55 |
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.55 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | CASP1 | P29466 | 1/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 5/20 | 0.54 |
| ▸ | POLB | P06746 | 3/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24021437 | 1.00 | HTT (0.64) | HTTALOX15PLK1ARDOT1L | |
| SCHEMBL29845556 | 1.00 | HTT (0.64) | HTTALOX15PLK1ARDOT1L | |
| Hydrochloric Acid SCHEMBL3701824 | 0.98 | HTT (0.62) | HTTALOX15PLK1ARDOT1L | |
| Quinoline SCHEMBL28128756 | 0.95 | HTT (0.59) | HTTALOX15PLK1ARDOT1L | |
| SCHEMBL28180456 | 0.91 | ALOX15 (0.62) | HTTALOX15PLK1ARDOT1L | |
| Isoquinoline SCHEMBL28125703 | 0.87 | AR (0.52) | HTTALOX15PLK1ARDOT1L | |
| SCHEMBL2232014 | 0.86 | ALDH1A1 (0.55) | HTTALOX15PLK1ARDOT1L | |
| SCHEMBL31068033 | 0.86 | ALDH1A1 (0.55) | HTTALOX15PLK1ARDOT1L | |
| SCHEMBL27856105 | 0.85 | DOT1L (0.73) | HTTALOX15PLK1DOT1LHDAC1 | |
| Quinoline SCHEMBL28125384 | 0.85 | ALDH1A1 (0.55) | HTTALOX15PLK1ARDOT1L |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 392 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3597184-B1 | INDANONE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS OR OPTICAL ISOMERS THEREOF, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING VIRAL DISEASES | KOREA RES INST CHEMICAL TECH (KR) | 2026-03-04 | — | — | EP | claimed |
| EP-4389747-A1 | IMIDAZO[1,2-A]PYRIDINE AND IMIDAZO[1,2-A]PYRAZINE DERIVATIVES AS MLLT1 AND MLLT3 INHIBITORS | Dark Blue Therapeutics Ltd (GB) | 2024-06-26 | — | — | EP | claimed |
| US-11884647-B2 | Compounds and methods for targeting pathogenic blood vessels | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-01-30 | — | — | US | claimed |
| CN-116375549-A | Method and system for synthesizing amide compound from nitrile compound | 深圳湾实验室 | 2023-07-04 | — | — | CN | claimed |
| US-20230159510-A1 | NOVEL PRMT5 INHIBITORS | AMGEN INC. (US) | 2023-05-25 | — | — | US | claimed |
| CN-111787922-A | Combination therapy for the treatment of hepatocellular carcinoma | 卫材 R&D 管理有限公司 | 2020-10-16 | — | — | CN | claimed |
| CN-110312511-A | pharmaceutical composition | 大鹏药品工业株式会社 | 2019-10-08 | — | — | CN | claimed |
| CN-105814040-B | The condensed 1,4- dihydro two of inhibitor as thermal excited transcryption factor 1 dislikes ene derivative | 癌症研究科技有限公司 | 2019-07-30 | — | — | CN | claimed |
| CN-110035995-A | MAChR M4Positive allosteric modulators | 范德比尔特大学 | 2019-07-19 | — | — | CN | claimed |
| CN-106565682-B | Substituted indole expires ketone derivatives and application thereof | 沈阳药科大学 | 2019-07-16 | — | — | CN | claimed |
| EP-1299395-B1 | OXAZINOQUINOLONES USEFUL FOR THE TREATMENT OF VIRAL INFECTIONS | UPJOHN CO (US) | 2004-09-15 | — | — | EP | claimed |
| WO-2004019933-A1 | METHOD OF PREVENTING OR TREATING ATHEROSCLEROSIS OR RESTENOSIS | PHARMACIA & UPJOHN COMPANY (US) | 2004-03-11 | — | — | WO | claimed |
| EP-0839145-B1 | HETEROCYCLYLCARBOXAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | ABBOTT GMBH & CO KG (DE) | 2003-11-05 | — | — | EP | claimed |
| EP-1299395-A1 | OXAZINOQUINOLONES USEFUL FOR THE TREATMENT OF VIRAL INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 2003-04-09 | — | — | EP | claimed |
| EP-1299387-A1 | HETEROCYCLE CARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2003-04-09 | — | — | EP | claimed |
| CN-1361768-A | Metabotropic glutamate receptor antagonists and their use for treating central nervous system disorders | NPS PHARMA INC (US) | 2002-07-31 | — | — | CN | claimed |
| WO-2002004462-A1 | OXAZINOQUINOLONES USEFUL FOR THE TREATMENT OF VIRAL INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 2002-01-17 | — | — | WO | claimed |
| WO-2002004445-A1 | HETEROCYCLE CARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2002-01-17 | — | — | WO | claimed |
| WO-1998045272-A1 | TOPOISOMERASE INHIBITORS | LATROBE UNIVERSITY (AU) | 1998-10-15 | — | — | WO | claimed |
| CN-86107819-A | Heterogeneous ring compound | — | 1987-06-10 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159510-A1 | NOVEL PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | HTT 3702/4885ALOX15 3322/4885PLK1 380/4885 |
| US-11884647-B2 | Compounds and methods for targeting pathogenic blood vessels | TEK, KDR, LIPG | HTT 2091/4885ALOX15 1739/4885PLK1 657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.